ESMO 2012: Pazopanib, Another Drug in the Arsenal of Weapons Against Renal Cell Cancer

ESMO 2012: Pazopanib, another drug in the arsenal of weapons against renal cell cancer – Cora Sternberg describes an interesting phase III study confirming the positive results for a new drug in RCC treatment. This study was presented during ESMO 2012, the Congress of the European Society for Medical Oncology. Read all the news about the latest in cancer and oncology from the Congress here www.esmo.org The opinion expressed in this interview reflects that of the interviewee and does not necessarily express the official ESMO point of view.

Lilly shares rise after report on cancer treatment

Filed under: drug treatment news 2012

Lilly shares rise after report on cancer treatment. By The Associated Press on October 15, 2012. Tweet; Facebook; LinkedIn; Google Plus; Comments · Print … Shares of Eli Lilly and Co. started the week strong after the drug developer said Monday a …
Read more on Businessweek

Aegerion Shares Rise on Report of High Cholesterol Drug

Filed under: drug treatment news 2012

Aegerion Pharmaceuticals Inc. (AEGR) rose after a U.S. regulatory staff report said a plan to manage the risks of the company's drug supports its approval in adults with the most life-threatening forms of severely high cholesterol. Aegerion gained 9.4 …
Read more on Businessweek